– We are concentrating our efforts on multiple areas that are directly linked to the Genomtec ID platform. Our main focus lies in conducting comparative studies in France and Poland of the Genomtec ID platform and the 5-plex panel for detecting respiratory tract infections. The objective is to register these products under the IVD Regulation (IVDR) before 2025. We are also prioritizing the scalability of reaction card production and cost optimization for reagents and cards themselves – said Miron Tokarski, CEO and major shareholder of Genomtec, in an interview with to Gazeta Giełdy i Inwestorów Parkiet.
Full article: https://www.parkiet.com/medycyna-i-zdrowie/art38709031-genomtec-coraz-blizej-komercjalizacji
